TriviumVet CEO Louise Grubb co-authors paper on ground-breaking Tavocept veterinary application

Human oncology drug Tavocept has been clinically evaluated for use in veterinary incidences of TCC (Transitional Cell Carcinoma). The study found that Tavocept decreased diuresis time and volume in dogs with bladder cancer receiving Cisplatin. A link to the full publication can be found here.

Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest